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1. Introduction 
High dose melphalan supported by autologous hematopoietic cell transplantation (AHCT) 
has been shown to prolong survival and decrease relapse rates compared to conventional 
chemotherapies in elligible patients with plasma cell myeloma (PCM) (Attal et al., 1996; 
Child et al., 2003; Fermand et al., 2005; Koreth et al., 2007; Palumbo et al., 2004). Patients 
who are considered candidates for high dose therapy receive 2-4 cycles of non-melphalan 
containing induction therapies followed by peripheral blood progenitor cell(PBPC) 
mobilization and collection. Pateints proceed to high dose melphalan (200 mg/m2) 
supported with AHCT. High dose melphalan and AHCT has been the gold standard 
treatment approach in patients with PCM younger than 65 but can be extended to mid-70’s 
in patients otherwise in good performance status. Second AHCT has been shown to increase 
survival, especially those who could not achieve very good partial response (VGPR) after 
the first AHCT (Attal et al., 2003, Barlogie et al., 2006). Additionally, patients who had a long 
progression free survival after the first transplantation may benefit from salvage 
transplantation at relapse (Ljungman et al., 2010). These advances have mandated the 
mobilization and collection of PBPCs adequate for double transplants. Although not 
prospectively studied, the traditional minimum and optimum CD34+ cell dose limits have 
been 2 x 106/kg and ≥ 4 x 106/kg for single ; 4 x 106/kg and ≥ 8-10 x106/kg for double 
AHCT, respectively (Bensinger et al., 1995, Giralt et al., 2009). Therefore, successfull stem 
cell mobilization and collection are crucial for treatment of PCM. Risk factors such as age 
>60 years, the extend of prior chemotherapy or radiotherapy and prolonged disease 
duration are recognized predictors for poor mobilization. The induction treatment given 
before the process of PBPC mobilization and collection should not be toxic to the bone 
marrow. It has been clearly revealed over the past decades that the traditional induction 
regimens; vincristine, adriamycin, dexamathasone (VAD) or single agent dexamathasone 
have no impact on PBPC mobilization. However, today, they have been completely replaced 
with novel agents which are associated with better response rates. During the recent years, 
the impact of these novel induction agents (thalidomide, lenalidomide and bortezomib) on 
PBPC mobilization have been of major concern. Although the classical PBPC mobilization 
methods (G-CSF alone or G-CSF after chemotherapy) have been generally successful in 
PCM, there is still a considerable amount of mobilization failures. Studies have been focused 
on the investigational agents alone or in conjunction with G-CSF to imrove PBPC 
mobilization efficiency, prevent mobilization failures and the need for second or subsequent 
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mobilization attempts which often delay the timely performance of the transplantation and 
increase the morbidity and the cost. In this chapter, we will focus on the current stem cell 
mobilization strategies as well as the novel mobilizing agents in PCM and the impact of 
novel anti-myeloma drugs on PBPC mobilization. 
2. Mobilization approaches in PCM 
2.1 G-CSF alone 
The optimal PBPC mobilization strategy in PCM is unclear. Both growth factor alone or 
chemotherapy followed by growth factor (chemomobilization) have been the most 
frequently used approaches. In growth factor-only mobilization, recombinant human 
granulocyte-colony stimulating factor (G-CSF) is commonly administered at 10 μg/kg/day 
s.c. for 4 days , PBPCs are collected from day 5 onwards and G-CSF continued until the last 
day of apheresis. PBPCs are collected by continuous flow apheresis procedure often 
processing 2-2.5 times the patient’s blood volume. CD34+ cell enumeration is performed by 
flow cytometry according to the ISHAGE guidelines(Sutherland et al., 1996). The stem cell 
product is then cryopreseved until use for AHCT. Recombinant human G-CSF is reliable, 
with predictable mobilization efficiency. The most common toxicities observed during G-
CSF administration such as bone pain, low grade fever, headache, are generally managable. 
However, G-CSF may be associated with rare serious adverse events such as spontaneous 
splenic rupture, thrombosis, flare of autoimmune disease and precipitation of sickle crisis 
(Cashen et al., 2007).  
2.2 G-CSF analogs 
2.2.1 Filgrastim and lenograstim 
Filgrastim (Neupogen, F Hoffmann-La Roche, Basel, Switzerland) and lenograstim 
(Granocyte, Chugai-Aventis Pharmaceuticals, France) are nonglycosylated and glycosylated 
analogs of recombinant human G-CSF approved for PBPC mobilization. Studies 
investigating the patients with hematological malignancies who underwent PBSC 
mobilization for AHCT could not demonstrate any difference between glycosylated and 
non-glycosylated G-CSF in terms of both efficacy and toxicity (Kopf et al., 2006; Lefrere et 
al., 1999). The glycosylation of G-CSF contributes to a greater chemical-physical stability of 
lenograstim: the glycosylated G-CSF is more stable and resistant to degradation. The 
recommended dosage of lenograstim when used alone for PBPC mobilization is 5 μ/kg/day 
(s.c./i.v.). On the other hand, equal doses of 10 μ/kg/day of filgrastim and lenograstim 
have been recommended for mobilization of CD34+ cells without associated chemotherapy. 
However, a recent study has suggested that lower dose (7.5 μ/kg/day) of glycosylated G-
CSF may be as effective as the standard dose of non-glycosylated G-CSF for PBPC 
mobilization in patients undergoing AHCT (Ataergin et al., 2008).  
2.2.2 Pegfilgrastim 
Pegylated G-CSF (pegfilgrastim, Neulasta, Amgen Inc.,CA, USA) is currently approved by 
the US FDA for prevention of prolonged neutropenia after chemotherapy for nonmyeloid 
malignancies (Neulasta; package insert). Its potential in PBPC mobilization is currently 
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being explored. Due to its long plasma half-life compared to unconjugated G-CSF (33 vs 4-6 
hours), it has the advantage of maintaining clinically effective serum levels over about two 
weeks after a single 6mg s.c. administration and achieving patient compliance. Its effect is 
self-limited and is terminated with cellular uptake by the recovering neutrophils (Hunter et 
al., 2003; Molineux et al., 1999). Clinical studies have demonstrated that pegfilgrastim is at 
least as efficient as filgrastim in mobilizing PBPCs after chemotherapy and this effect was 
not dose dependent. Pegfilgrastim was associated with a more rapid leukocyte recovery and 
an earlier performance of the first apheresis procedure in comparison to unconjugated G-
CSF in PCM patients (Bruns et al., 2006; Fruehauf et al., 2007; Stiedl et al., 2005). 
Additionally, in a tandem transplant study, PBPC mobilization with chemotherapy plus 
pegfilgrastim in 237 PCM patients, a second booster injection of 6mg pegfilgrastim on day 
13 after an initial administration on day 6, improved the serum G-CSF concentrations and 
the mobilization results (Tricot et al., 2008). In contrast to mobilization after chemotherapy, 
growth factor-only mobilization requires higher doses of pegfilgrastim to provide effective 
serum G-CSF levels (Hosing et al., 2006; Willis et al., 2009). However, this approach is not 
cost-effective when compared with unconjugated G-CSF. Pegfilgrastim is well tolerated 
with an advese event profile similar to that of unconjugated G-CSF. Bone pain is the most 
common complaint and a case of splenic rupture that may not have been related to 
pegfilgrastim was reported in one trial (Fenk et al., 2006). 
2.3 Chemomobilization 
The standard chemomobilization in myeloma consists of cyclophosphamide(CY) plus 
growth factor (Goldschmidt et al., 1996). High dose CY has been prefered in patients who 
fail initial mobilization attempt with growth factor only or for patients who could not 
achieve at least partial remission after induction regimens with the hope to control the 
high tumor burden before transplantation. However, it has been demonstrated that high 
dose CY does not increase overall complete remission rates or improve the time to 
progression for patients with myeloma undergoing AHCT (Dingli et al., 2006). At our 
center, CY 4 gr/m2 with the same dose MESNA to prevent hemorrhagic cystitis is 
administered on day 1 and recombinant human G-CSF (10 μg/kg/day, in two divided 
doses) is started either on day 4 or day 7. The optimal timing for G-CSF initiation has not 
been determined conclusively. We have demonstrated that late (day 7) administration of 
G-CSF was as efficient and more cost-effective than early administration (Ozcelik et al., 
2009). Flow cytometric quantification of peripheral blood(PB) CD34+ cells is performed 
when the WBC count reaches >1000/μl from the chemotherapy induced nadir. The 
apheresis is started when PB CD34+ cell count exceeds 10 cells/μl and continued until 
adequate number of CD34+ cells are collected usually for 1-3 apheresis procedures. 
Transfusion support should be given to keep the pre-apheresis Hb and platelet counts at ≥ 
10gr/dl and ≥ 20 000-30 000/μl, respectively. 
The dose of CY reported for mobilization has ranged from 1.5 to 7 gr/m2. Retrospective 
studies comparing CY doses of 4 gr/m2 versus 7 gr/m2 and 1.2-2 gr/m2 versus 4 gr/m2 have 
favored lower doses because of similar stem cell mobilization efficiency but with 
considerably lower toxicity (Fitoussi et al., 2001; Jantunen et al., 2003). In a randomized 
study in myeloma patients comparing single dose 7 g/m2 with 2.4 g/m2 , higher number 
CD34+ cells were collected on the first apheresis day and there was a lower consumption of 
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G-CSF with the lower-dose CY regimen, which also permitted collection to occur as an 
outpatient procedure and was more cost-effective (Petrucci et al., 2003). Hiwase et al in their 
retrospective analysis have demonstrated that compared with low dose (1-2 gr/m2) CY, 
patients receiving intermediate dose (3-4 gr/m2) CY were more likely to collect the CD34+ 
cell number (≥4 x106/kg) adequate for tandem transplant. Febrile neutropenia was more 
frequent in intermediate dose CY group (38% vs 13%) but the increased toxicity was 
managable and acceptable (Hiwase et al., 2007). In the light of these studies, most centers 
prefer 3-4 gr/m2 CY in their chemomobilization protocol (Gertz et al., 2010a).  
High dose CY plus G-CSF is very efficient for PBPC mobilization in PCM patients but when 
compared with growth factor-only mobilization, chemotherapy plus growth factor 
mobilizes higher number of PBPCs in lower number of apheresis procedures but with the 
cost of increased toxicity; nausea- emesis, neutropenic fever, non-staphylococal bacteremia, 
sepsis, hemorrhagic cystitis, cardiac toxicity, hospitalization, requirement for transfusion 
support and with mortality rate of 1-2%. Moreover, there is increased possibility of delayed 
engraftment after AHCT if transplanted early after (e.g. <30 days) stem cell procurement 
(Gertz et al., 2009; To et al., 1990).  
With the purpose of decreasing toxicity and at least preserving the efficiency, various 
alternative chemomobilization protocols with or without CY have also been investigated. 
Addition of etoposide (2 gr/m2) to CY (4.5 gr/m2) mobilization in a non-randomized 
study, resulted in increased toxicity without significant improvement in CD34+ cell yield 
(Gojo et al., 2004). In CAD protocol, CY (1gr/m2, day 1) was combined with doxorubicin 
(15 mg/m2, day 1-4) and dexamethasone (40 mg, day 1-4) followed by a single dose 12 mg 
pegfilgrastim on day 5. Eighty-eight percent of patients achieved their CD34+ cell harvest 
target of 7.5 x 106 CD34/kg following a median of two apheresis. Mobilization efficiency 
and engraftment following transplantation using pegfilgrastim was comparable to 
filgrastim and patients mobilized with CAD plus pegfilgrastim had decreased time to first 
apheresis (13 vs 15 days)(Fruehauf et al., 2007). The former common induction protocol 
VAD followed by daily G-CSF 10 μg/kg from day 10 to day 15 was found to be as 
effective and less toxic than high-dose CY followed by daily G-CSF 5 μg/kg from day 8 in 
newly diagnosed myeloma patients (Lefrère et al., 2006). Blood stem cell collection results 
after mobilization with combination chemotherapy containing ifosfamide, epirubicin, and 
etoposide (IEV) followed by G-CSF in myeloma were favorable and allowed to support a 
tandem transplantation procedure in younger and elder patients in 97 and 95%, 
respectively. Grade ¾ hematological toxicity was observed in majority of patients and 
extramedullary toxicity including nephrotoxicity and neurotoxicity in 5–10% (Straka et al., 
2003). IEV mobilized peripheral blood stem cells more efficiently than cyclophosphamide 
and etoposide, achieving a threshold of 6 x 106 CD34/kg in 97 vs. 71% with comparable 
major toxicities and similar tumor response rates, although there was one treatment-
related death due to septic shock in the IEV chemotherapy group (Hart et al., 2007). DCEP 
protocol includes dexamethasone (40 mg/d, day 1-4 ) , CY 400 mg/m2, etoposide 40 
mg/m2 and cisplatin 10 mg/m2, daily continuous infusion for 4 days and has proved to be 
an effective salvage therapy for relapsed/refractory myeloma patients. G-CSF 5 
μg/kg/day starting 48 h after the end of DCEP has been an effective mobilization 
protocol with 87 and 75% of patients achieving ≥ 2 x 106 and >4 x 106 /kg CD34+ cells, 
respectively (Lazzarino et al., 2001). The same group of investigators compared DCEP 
with CY (4 g/m2) followed by G-CSF and concluded that DCEP is better tolerated and 
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more effective than CY for PBPC mobilization. Moreover, high-dose CY has limited anti-
myeloma activity compared to DCEP. One study demonstrated the comparable efficiency 
and lower toxicity of shorter-infusional schedule of DCEP with respect to full-infusional 
schedule (Corso et al., 2002, 2005). Another study combined DCEP-short with a single 
dose 6mg s.c. pegfilgrastim and reported promising results (Zappasodi et al., 2008). In a 
pilot study, vinorelbin combined with CY 1.5 g/m2 had similar efficiency compared to CY 
4 g/m2 in PBPC mobilization and less toxicity and no requirement for hospitalization 
(Annunziata et al., 2006). Melphalan i.v. 60mg/m2 plus G-CSF 10 μg/kg/day was 
successful in mobilizing PBPC from myeloma patients. However, toxicity was notable and 
duration of mobilization was longer compared with CY 3 g/m2 (16.5 days vs 10 
days)(Gupta et al., 2005). Melphalan is a highly effective anti-myeloma drug but due to its 
stem cell toxicity, it is neither used for PBSC mobilization, nor recommended as an initial 
therapy for patients elligible for AHCT. In a retrospective analysis, single agent etoposide 
(1.5 g/m2) plus G-CSF was most potent at mobilizing PBPCs compared to CY (2-4 g/m2) 
plus G-CSF or G-CSF alone. Although the success rate for collecting the minimum CD34+ 
dose was similar in all groups, higher proportion of patients mobilized with etoposide 
could achieve the optimum dose required for tandem transplant. There was no difference 
in the progression free survival among the groups (Nakasone et al., 2009). Recently, in a 
retrospective single center review, intermediate dose etoposide (375 mg/m2, day 1 and 2) 
followed by G-CSF was found to be highly effective in myeloma patients including the 
high risk patients for mobilization failure (Wood et al., 2011). However, myelosuppressive 
mobilization regimens neither seem to have any anti-myeloma effects nor appear to 
improve outcome (Attal et al., 2003). And most centers no longer routinely use CY for 
patients in first plateau.  
3. High risk patients for mobilization failure  
Although there may be variations in each center’s definition of mobilization failure, 
generally it can be defined as lack of achievement of ≥ 2 x106/kg CD34+ yield after 3 
consecutive apheresis procedure or inability to start apheresis because of not reaching to >10 
CD34+ cells/μl of PB . Extensive BM involvement with malignancy, prior radiotherapy 
especially to marrow-rich sites, prior treatment with alkylating agents, prior multiple 
chemotherapy regimens and older age have been associated with increased risk of 
mobilization failure (Bensinger et al., 2009; Demirer et al., 1996; Leung et al., 2010). Although 
the number of CD34+ cells collected decreases with increasing age, the experience has 
revealed that sufficient stem cell yield for ≥ 1 AHCT can be safely obtained in elderly 
patients up to 69-72 years (Roncon et al., 2011; Tempescul et al., 2010). On the other hand, in 
one retrospective study including myeloma and lymphoma patients, the total number of 
cycles of previous chemotherapy and previous treatment with melphalan were more 
significant predictors of poor mobilization than sex, age or body weight (Wuchter et al., 
2010). Recently, prior prolonged exposure to novel agent lenalidomide has also been 
considered as a risk factor, which will be discussed later. With the current mobilization 
strategies about 5-10% of patients with PCM still end up with mobilization failure 
(Bensinger et al., 2009; Pusic et al., 2008). The classical strategy when patients fail G-CSF 
only mobilizations has been CY followed by G-CSF. However, this results in unnecessary 
exposure of the patients to chemotherapy toxicity for sole mobilization purposes, which 
means that novel PBPC mobilization approaches are required. 
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4. Novel agents for PBPC mobilization 
Historically, attempts to increase the mobilization efficiency concentrated on using high 
doses of G-CSF or combining G-CSF with other cytokines and growth factors some of which 
are currently used in other indications. However, either due to inefficiency or AEs, most of 
these agents could not become a part of the standart mobilization. In recent years, several 
cytokines and chemokines have been investigated that may prove useful for amplifying 
yields of CD34+ cells without introducing additional toxicity. There are also investigational 
agents which are yet in preclinical and phase I clinical trials (Table 1) (Bakanay & Demirer, 
2011). 
 
 
Growth Factors 
Granulocyte-Macrophage Colony Stimulating Factor 
Recombinant human erythropoietin 
Recombinant human stem cell factor  
Recombinant human thrombopoietin 
Parathyroid hormone 
Recombinant human growth hormone 
 
 
Chemokine axis mobilizers 
AMD3100  
GRO-β analogs (SB-251353) 
 
 
Other small molecules and peptides 
Very Late Antigen-1 antibodies 
Retinoic acid receptor alpha agonists 
Thrombopoietin receptor agonists  
 
Table 1. Agents investigated as adjunct to G-CSF for PBPC mobilization 
4.1 Plerixafor 
Plerixafor (AMD3100, Mozobil, Genzyme Corporation, Cambridge, MA, USA) is a bicyclam 
molecule which selectively and reversibly antagonizes CXCR4 and disrupts its interaction 
with stromal cell derived factor-1 (SDF-1), thereby releasing hematopoietic stem cells into 
the circulation (Gerlach et al., 2001; Hendrix et al., 2000). Plerixafor has received approval by 
the US FDA and the European Medicines Evaluation Agency for use in combination with G-
CSF to mobilize PBPCs for collection and subsequent AHCT in patients with NHL and PCM 
who previously failed mobilization with G-CSF alone (DiPersio et al. 2009a,2009b; Mozobil 
package insert). Plerixafor results in rapid mobilization of PBPC, which peaks at 
approximately 10 hours. Plerixafor has been shown to synergize with G-CSF for mobilizing 
stem cells in patients with PCM in various clinical conditions (Calandra et al., 2008; DiPersio 
et al., 2009a; Flomenberg et al., 2005; Stiff et al., 2009; Tricot et al., 2010). The results from 
phase II studies indicated that plerixafor added to G-CSF for PBPC mobilization from 
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myeloma patients mobilized more CD34+ cells per day of apheresis than G-CSF alone (4.4 
vs 3-3.5 fold) with 95 to 100% of the patients achieving the minimum number ( ≥ 2 x106/kg) 
of target CD34+ cells in a median of 1-2 apheresis days. Even the heavily pretreated patients 
had the median 2.5 fold increase in the PB CD34+ cells and could proceed with high dose 
therapy and AHCT (Stewart et al., 2009; Stiff et al., 2009). In a randomized, placebo-
controlled phase III study the proportion of patients from whom ≥ 6 x106 CD34+ cells/kg 
were collected in ≤2 days of apheresis served as the primary end point. The protocol for 
plerixafor plus G-CSF mobilization has been summarized(Table 2). The results 
demonstrated that the addition of plerixafor to G-CSF resulted in a significantly higher 
probability of achieving the optimal CD34+ cell target for tandem transplantation in fewer 
days of apheresis in PCM patients without any additional toxicity(Table 3). Peripheral blood 
stem cells mobilized by plerixafor and G-CSF resulted in prompt and durable engraftment 
after AHCT(DiPersio et al., 2009a).  
 
GCSF 10 μg/kg/day s.c. on days 1-4 
Plerixafor 240 μg/kg/day s.c. started on the evening of day 4 
Apheresis initiated 10 h after the first dose of plerixafor on the morning of day 5 
Daily GCSF before apheresis in the morning and plerixafor in the evening 
Continued until the target CD34+ cells ≥ 6 x 106/kg was collected or a predetermined 
maximum number of apheresis (4-5) was reached 
Table 2. Mobilization protocol of Plerixafor plus GCSF  
 
 
Plerixafor + G-CSF 
N=148 
Placebo + G-CSF 
N=154 
Achieved primary end point (%) 71.6 34.4 
Achieved min. collection (%) 95.9 92.9 
Fold increase PB CD34/μl  4.8 1.7 
Median number of apheresis 
days to collect the target  
1 4 
Median(range) collected CD34 
cells x106/kg  
10.96  
(0.66-104.57) 
6.18  
(0.11-42.66) 
Failed mobilization (%) 0 4.6  
Table 3. Phase III Clinical trial of PBPC mobilization with Plerixafor plus G-CSF in PCM  
There is lack of sufficient information on direct comparison of mobilization with G-CSF and 
plerixafor to mobilization with chemotherapy and G-CSF. In a retrospective comparison, 
both G-CSF plus plerixafor and CY plus G-CSF resulted in similar numbers of cells collected 
as well as costs of mobilization and clinical outcomes (Shaughnessy et al., 2011). For the 
patients from whom sufficient number of CD34+ cells could not be collected after the first 
mobilization attempt with G-CSF alone, a second(rescue) mobilization has been traditionally 
attempted with chemotherapy plus G-CSF. However, instead of chemomobilization, a 
rescue stem cell mobilization with G-CSF and plerixafor can be offered in patients who only 
require PBPC mobilization and collection without any need for further tumor reduction. In 
compassionate use programs, plerixafor has been used successfully in myeloma patients 
who were either proven or predicted to be poor mobilizers. About 75% of the patients could 
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be rescued after failure from chemotherapy (Basak et al., 2011a; Calandra et al., 2008; Duarte 
et al., 2011). Plerixafor plus G-CSF can also be an option for myeloma patients who had 
received a previous AHCT and who require a repeated mobilization for a second 
transplantation. In a recent study, successful mobilization of PBPCs was performed in a 
similar proportion of the previously transplanted patients and other patients who had not 
undergone ASCT (70% vs 82.6%) (Basak et al., 2011b).  
Plerixafor combined with chemotherapy and G-CSF in a recent open-label, multicenter trial 
on 40 patients with PCM and NHL, also proved to be a feasible method of stem cell 
mobilization. However, further studies are warranted to evaluate the exact timing of 
incorporating plerixafor into chemomobilization (Dugan et al., 2010). Table 4 gives a single 
center approach to mobilization in the era of novel mobilizing agent, plerixafor (Gertz, 
2010b). In one single center experience, preemptive use of plerixafor was successful in 
patients who had either PB CD34+ counts <10/μl at the time of marrow recovery or poor 
yield of first apheresis CD34+ <1x 106 /kg (Jantunen et al., 2011). Similarly, a promising 
approach with growth factor and patient-adapted use of plerixafor has been recently 
suggested to be superior to chemotherapy and growth factor for autologous PBPC 
mobilization. The preemptive use of plerixafor using the PB CD34+ cell count on day 4 of G-
CSF administration and the collection target to decide between continuing G-CSF only or 
adding plerixafor to the mobilization regimen may potentially reduce the percentage of 
failure in first-line mobilizations (Costa et al., 2011a, 2011b). A recent study demonstrated 
that the quantity of CD34+ cells collected on day 1, rather than the PB CD34+ cell count, 
might identify patients unlikely to achieve adequate stem cell collection for AHCT and 
suggested that patients who collect <0.70 x106 CD34+ cells/kg on day 1 could be considered 
for treatment modifications such as adding plerixafor (Duong et al., 2011). 
 
 
G-CSF 10 μg/kg single dose x 4 days 
If collecting for 1 transplant: if CD34+ < 10 x 106/L, add plerixafor  
If collecting for >1 transplant: if CD34+ < 20 x106/L, add plerixafor  
 
 
If relapsed or primary refractory myeloma or circulating plasma cells:  
CY 1.5 g/m2 x 2 days, begin G-CSF 5 μg/kg on day 3  
Check CD34+ when WBC >1000 x 106/L.  
If CD34+ < 10 x 106/L continue to check for three consecutive days.  
If CD34 remains < 10 x106/L, begin plerixafor 
 
Table 4. The Mayo Clinic Rochester approach to PBPC mobilization in myeloma  
Plerixafor is well tolerated and adverse events are usually mild and transient. The most 
common adverse events are diarrhea, nausea, vomiting, flatulance and injection-site 
reactions, fatigue, arthralgia, headache, dizziness and insomnia. Severe adverse events such 
as hypotension and dizziness after drug administration and thrombocytopenia after 
apheresis are very rare (DiPersio et al., 2009, Mozobil package insert). No case of splenic 
rupture due to plerixafor has been reported to date. No evidence of tumor cell mobilization 
could be demonstrated after plerixafor in PCM and NHL patients(Fruehauf et al., 2010). A 
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plerixafor dose reduction to 160 µg/kg in patients with a creatinine clearance value ≤ 50 
mL/min is recommended (Douglas et al., 2011; MacFarland et al., 2010; Pinto et al., 2010). 
Plerixafor addition to G-CSF has undoubtedly increased the number of patients who could 
proceed with high dose therapy and AHCT. Plerixafor incorporation in the first line 
mobilization protocols in patients who are predicted poor mobilizers will eliminate the need 
for further mobilization attempts and the cost-effectiveness of such approaches should be 
clarified. Recently, the International Myeloma Working Group(IMWG) have proposed some 
strategies to overcome the risk factors for poor PBPC mobilization in PCM (Giralt et al., 
2009) (Table 5). 
 
Risk Factor Proposed strategy 
Age>60  Consider plerixafor 
History of melphalan exposure 
Consider upfront chemomobilization or 
plerixafor 
Extensive prior therapy and prolonged 
disease duration 
Harvest early between cycles 2-4 
Consider upfront plerixafor or 
chemomobilization 
Assess marrow for secondary dysplastic 
changes before collection 
Extensive radiotherapy to marrow bearing 
tissue 
Consider collection before radiotherapy 
Consider upfront chemomobilization or 
plerixafor 
Assess marrow for secondary dysplastic 
changes before collection 
Table 5. Strategies proposed by IMWG to overcome the risk factors for poor PBPC 
mobilization in PCM 
5. The effect of novel induction protocols on PBPC mobilization in PCM 
Until the last decade, the standard first line therapy for PCM has been either VAD or single 
agent dexamethasone. These therapies clearly do not have any adverse effects on PBPC 
mobilization from the bone marrow. However, they have been replaced by more efficient 
novel agents such as IMIDs ( thalidomide and lenalidomide) and proteosome inhibitor 
bortezomib. Novel induction agents in myeloma are effective as first line therapy enhancing 
the quality of responses prior to AHCT and by controlling the tumor load at diagnosis they 
decrease the early mortality and prolong the overall survival. With the novel induction 
agents, the time from diagnosis to planned AHCT is shorter and most patients can achieve ≥ 
VGPR after the transplantation which eliminates the need for tandem AHCT for most 
patients. In fact it also neccesitates re-exploration of the role of first line AHCT in selected 
patients, moving AHCT to a second line position. The novel agents are also used as adjuncts 
to transplant conditioning regimen or as maintenance therapy after transplant (Dimopoulos 
et al., 2007; Harousseau et al., 2010; Kumar et al., 2009; Rajkumar et al., 2006).  
5.1 Thalidomide 
The IMIDs have antiangiogenesis, immunomodulatory activity and direct cyctotoxic affects 
on myeloma cells. Pretransplant treatment with IMIDs appear to have no impact on 
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engraftment kinetics suggesting that both thalidomide and lenolidomide do not have 
qualitative effects on stem cells. Thalidomide was the first IMID to be used in PCM and 
initial therapy with thalidomide-dexamethasone (thal/dex) was superior to dexamethasone 
alone (Rajkumar et al., 2006). Although there has been controversial reports, most studies 
have shown no impact of thalidomide on stem cell mobilization and >80% of patients who 
received thal/dex were able to collect adequate stem cells for tandem transplant (Cavo et al., 
2005). In a phase III randomized study, patients treated with induction regimen TAD 
(Thalidomide, doxorubicine, dexamethasone) had fewer CD34+ cell collection following 
CAD plus G-CSF mobilization than patients who received VAD as induction. However, the 
number of CD34+ cells were sufficient to support double AHCT in 82% of TAD treated 
patients (Breitkreutz et al., 2007). However, in a recent study thalidomide in combination 
with CY and dexamethasone (CTD) as induction regimen had significantly (49%) lower 
PBPC yield and higher percentage of mobilization failures for one (25.4 vs 5.8%) or two (39.4 
vs 15.9%) transplants compared with VAD and a VAD-like induction regimen. The authors 
have pointed that thalidomide and CY with no previously reported negative impact on stem 
cell mobilization can have substantial impact when used in combination (Auner et al., 2011). 
5.2 Lenalidomide 
Lenalidomide in combination with dexamethasone (Len/dex) have been associated with 
better outcomes and improved survival rates in patients with PCM (Rajkumar et al., 2005, 
Dimopuolos et al., 2007, Wang et al., 2008). However, lenalidomide can cause 
myelosuppression and concerns have been raised that its use may negatively impact the 
ability to mobilize stem cells in patients who received lenalidomide as part of their 
induction therapies (Kumar et al., 2007; Mazumder et al., 2008; Paripati et al., 2008; Popat et 
al., 2009). Kumar have indicated that among patients mobilized with G-CSF alone there was 
a significant decrease in total CD34+ cells collected, average daily collection, day 1 collection 
and increased number of apheresis in patients treated with lenalidomide compared to 
patients treated with other regimens(Kumar et al., 2007). One retrospective analysis 
demonstrated higher mobilization failure rates with filgrastim among lenalidomide- treated 
patients compared with patients who had not received lenalidomide (25% vs 4%, p<0.001). 
Failure rate was very high in patients who received >3 cycles of lenalidomide. Majority of 
the lenalidomide-treated patients(77%) could be rescued with chemotherapy plus 
filgrastim(Popat et al., 2009). A multicenter prospective study of 346 patients with newly 
diagnosed PCM, has demonstrated that 21% of the patientswho received 4 cycles of len/dex 
as induction regimen, could not achieve the target 4 x 106 CD34+ cells/kg after CY plus G-
CSF mobilization whereas only 9% of patients failed after a second mobilization attempt 
with the same mobilization protocol. Lenalidomide as a part of the induction regimen did 
not adversely affect the PBPC mobilization and a second mobilization procedure with CY 
plus G-CSF may be an appropriate strategy to rescue poor mobilizers(Cavallo et al., 2011). In 
different studies where patients were mobilized after len/dex induction therapy, 
mobilization with CY plus G-CSF yielded clearly higher (range 6.3 to 14.2 x 106/kg) number 
of stem cells with respect to mobilization with G-CSF alone (range 3.1 to 7.9 x 106/kg) 
(Kumar et al., 2007; Mark et al., 2008; Mazumder et al., 2008; Paripati et al., 2008; Popat et al., 
2009). Incorporation of lenalidomide into induction therapy for PCM did not have clinically 
significant impact on PBPC mobilization when CY plus G-CSF was used as mobilization 
protocol. Sufficient stem cells for tandem auto-HCT were collected from all patients 
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mobilized with CY plus G-CSF versus only 33% of patients mobilized with G-CSF alone. 
Some studies demonstarted lower stem cell yield with increasing duration of lenalidomide 
therapy but other studies could not demonstrate such correlation (Mark et al., 2008; 
Mazumder et al., 2008; Nazha et al., 2011). Since addition of CY + G-CSF does not increase 
the responses to myeloma therapy, exposing patients to the risks of chemomobilization for 
sole mobilization purposes should be avoided. Plerixafor is a promising alternative to 
chemomobilization in patients with PCM who received prior therapy with lenalidomide. 
Retrospective data analysis for 60 patients who received plerixafor plus G-CSF for front-line 
mobilization in a phase 3 clinical trial or for remobilization in a compassionate use program 
demonstrated that CD34+ cells can be successfully and predictably mobilized and collected 
in majority of patients with PCM who have been previously treated with lenalidomide 
(Micallef et al., 2010) (Table 6). The IMWG have published the consensus report focusing on 
the approach to stem cell mobilization in era of novel agents in PCM (Kumar et al., 
2009)(Table 7). 
 
Frontline  
P + G-CSF 
Remobilization  
P + G-CSF 
Total 
Minimal ≥ 2 x 106 CD34+ 
cells/kg 
100% 80% 86.7% 
Optimal ≥ 5 x 106 CD34+ 
cells/kg 
95% 47.5% 63.3% 
Table 6. Mobilization response to Plerixafor plus GCSF in lenalidomide-treated patients 
5.3 Bortezomib 
Bortezomib is effective in patients with relapsed or refractory disease as well as in untreated 
patients No definitive impact of initial therapy with bortezomib on stem cell harvest could 
be demonstrated (Benson et al., 2010; Corso et al., 2010; Horousseau et al., 2010; Jagannath et 
al., 2005). In the IFM2005/01 trial comparing bortezomib/dexamethasone to VAD, there 
was a trend towards lower CD34+ numbers among those receiving bortezomib. However, a 
single mobilization with G-CSF was adequate and allowed the harvest of sufficient number 
of CD34+ cells for a single transplant in 97% and for a tandem transplant 77% of the patients 
treated upfront with bortezomib/dexamethasone. Compared with VAD, a higher number of 
patients in bortezomib/dexamethasone arm required a second mobilization attempt to 
reach the target 5 x 106 CD34+ cells/kg for tandem transplantation (Horousseau et al., 2010; 
Moreau et al., 2010). HOVON65/GMMG-HD4 randomized phase 3 trial comparing 
bortezomib, adriamycin, dexamethasone (PAD) versus VAD, no impact of bortezomib was 
seen on ability to collect stem cells (Goldschmidt et al., 2008).  
Studies combining bortezomib with lenalidomide or thalidomide also did not reveal any 
adverse effect of bortezomib on stem cell mobilization (Richardson et al., 2010; Bensinger et 
al., 2010; Kaufman et al., 2010). Simultaneous use of bortezomib in combination with 
thalidomide and chemotherapy (DT-PACE; cisplatin, doxorubicin, CY, etoposide and 
dexamethasone) was also effective, safe and allowed for adequate stem cell collection 
(Badros et al., 2006). Addition of alkylating agents to initial therapy especially in 
combination, may increase the risk of mobilization failures but no comparative data is 
available. Phase 2 studies combining CY with lenalidomide and CY with thalidomide 
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reported mobilization failures while combination of CY with bortezomib did not reveal any 
failure (Reeder et al., 2009).  
 
Condition  Recommended approach 
Initial therapy with thalidomide or 
bortezomib plus dexamethasone 
Patients who received <4 cycles of 
lenalidomide plus dexamethasone and 
younger than 65 years 
G-CSF alone 
Patients who received ≥4 cycles of 
lenalidomide plus dexamethasone 
CY + G-CSF 
Patients who received ≥4 cycles of 
lenalidomide plus dexamethasone and 
older than 65 years 
Reduced dose CY + G-CSF 
G-CSF alone with the addition of plerixafor 
before second apheresis if first apheresis 
yields <2 x 106 CD34+ cells/kg 
Patients who received other 
myelosuppressive drugs in combination 
with lenalidomide 
CY + G-CSF 
Failed mobilization with G-CSF alone in 
lenalidomide-treated patients 
CY + G-CSF 
G-CSF + Plerixafor  
G-CSF + GM-CSF 
Table 7. Approach to stem cell mobilization in era of novel agents in PCM : IMWG 
consensus perspectives  
6. Conclusions 
As the novel anti-myeloma drugs (thalidomide, lenalidomide, bortezomib) in combination 
with dexamethasone or other agents have replaced the traditional VAD or single agent 
dexamethasone as first line therapy for myeloma, there has been concern about their impact 
on PBPC mobilization from the bone marrow. Studies could not demonstrate any 
deleretious effect of bortezomib on stem cell mobilization. There has been contraversy 
regarding thalidomide’s impact especially when combined with other cytotoxic agents such 
as CY. However, the thal/dex combination has proved to allow for adequate PBPC yield for 
tandem transplantation. On the other hand, prolonged exposure to lenalidomide definitely 
affects the stem cell yield. Early PBPC mobilization with (<4 cycles) is recommended after 
lenalidomide-containing regimens. If this condition can not be satisfied, mobilization with 
CY+ G-CSF or addition of plerixafor to G-CSF should be considered. Although the 
integration of the novel anti-myeloma agents in the upfront treatment of PCM has started 
questioning the place of the high dose therapy supported with AHCT as first line approach, 
it is still the gold standard approach in elligible patients with PCM. This requires the 
mobilization and collection of adequate number of PBPCs following an initial induction 
threatment. Traditionally, G-CSF alone or after chemotherapy (mostly CY) have been the 
most commonly used protocols. Generally, CY plus G-CSF is used in the second 
mobilization attempt after failing G-CSF. However, this approach does not improve the 
overall outcome of the myeloma patients. So, it is unnecessary to expose the patients to toxic 
effects of chemotherapy for sole mobilization purposes. And the combined cytotoxic 
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chemotherapies are better reserved for relapsed or refractory cases. Current studies focus on 
the novel investigational agents as adjuncts to G-CSF to improve the PBPC yields. 
Plerixafor, which selectively and reversibly antagonizes CXCR4 and disrupts its interaction 
with SDF-1, has the ability of rapid mobilization of PBPCs from BM and gained approval as 
an adjunct to G-CSF for poor mobilizers. At the present, it is challenging to search for the 
best approach using the available drugs with appropriate timing to provide sufficient 
CD34+ yield after initial mobilization attempt and in a cost-effective manner avoiding 
further mobilization attempts and exposure to chemotherapy. 
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